Shilpa Medicare Limited (full production cycle; quality control and stability testing (physical and chemical tests))
UkraineAll drugs from this manufacturer
-
The drug is intended for the treatment of adult patients who are not candidates for stem cell transplantation, for the following diseases: intermediate-2 and high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
Dosage form: lyophilisate for solution for injection
Active substance Dosage azacitidine 100 mg ATC: L01BC07
-
The drug is used for the treatment of multiple myeloma (both as part of combination therapy and as monotherapy), as well as for the treatment of mantle cell lymphoma.
Dosage form: lyophilisate for solution for injection
Active substance Dosage bortezomib 3.5 mg ATC: L01XG01
-
The drug is used as part of conditioning therapy prior to hematopoietic stem cell transplantation (HSCT). It is used in adults and children in combination with other drugs (cyclophosphamide, melphalan, or fludarabine) depending on the treatment regimen.
Dosage form: concentrate for infusion solution
Active substance Dosage busulfan 6 mg/ml ATC: L01AB01
-
The drug is used for the treatment of colon cancer (colorectal cancer) and stomach cancer. It is also used for breast cancer.
Dosage form: tablets, film-coated
Active substance Dosage capecitabine 150 mg ATC: L01BC06
-
The drug is used to treat colon cancer (colorectal cancer) and stomach cancer. It is also used to treat breast cancer.
Dosage form: tablets, film-coated
Active substance Dosage capecitabine 500 mg ATC: L01BC06
-
The drug is indicated for the treatment of adult patients with newly diagnosed or secondary acute myeloid leukemia (AML) who, according to the WHO classification, are not candidates for standard induction chemotherapy.
Dosage form: lyophilisate for solution for injection
Active substance Dosage decitabine 50 mg ATC: L01BC08
-
The drug is intended for the treatment of adult patients with relapsing-remitting forms of multiple sclerosis, including clinically isolated syndrome and active secondary progressive disease.
Dosage form: capsules, modified release
Active substance Dosage dimethyl fumarate 120 mg ATC: L04AX07
-
Dimethylfumarate is indicated for the treatment of adult patients with relapsing-remitting forms of multiple sclerosis, including clinically isolated syndrome and active secondary progressive disease.
Dosage form: capsules, modified release
Active substance Dosage dimethyl fumarate 240 mg ATC: L04AX07
-
The drug is used for the treatment of non-small cell lung cancer (as first-line therapy or for maintenance after chemotherapy) and metastatic pancreatic cancer (in combination with gemcitabine).
Dosage form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
-
The drug is used for the treatment of non-small cell lung cancer (in the presence of certain EGFR mutations) and metastatic pancreatic cancer (in combination with gemcitabine).
Dosage form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
-
The drug is used for the treatment of non-small cell lung cancer (in the presence of certain EGFR mutations) and metastatic pancreatic cancer (in combination with gemcitabine).
Dosage form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
-
The drug is used to treat certain types of blood cancer (e.g., chronic myeloid leukemia and acute lymphoblastic leukemia), myelodysplastic diseases, hypereosinophilic syndrome, as well as for the treatment of gastrointestinal stromal tumors (GIST) and dermatofibrosarcoma.
Dosage form: tablets, film-coated
Active substance Dosage imatinib 100 mg ATC: L01XE01
-
The drug is used to treat certain types of blood cancer (chronic myeloid leukemia and acute lymphoblastic leukemia), myelodysplastic diseases, hypereosinophilic syndrome, as well as gastrointestinal stromal tumors (GIST) and dermatofibrosarcoma.
Dosage form: tablets, film-coated
Active substance Dosage imatinib 400 mg ATC: L01XE01
-
The drug is used to treat patients with metastatic colorectal cancer. It may be used as monotherapy or in combination with other drugs (for example, 5-fluorouracil, folinic acid, bevacizumab, cetuximab, or capecitabine).
Dosage form: concentrate for infusion solution
Active substance Dosage irinotecan 20 mg/ml ATC: L01XX19
-
The drug is prescribed to adults for the treatment of differentiated thyroid carcinoma (radioiodine-refractory), hepatocellular carcinoma (unresectable or progressing), as well as endometrial carcinoma (in combination with pembrolizumab).
Dosage form: capsules, hard
Active substance Dosage lenvatinib 10 mg ATC: L01EX08
-
The drug is prescribed to adults for the treatment of differentiated thyroid carcinoma (radioiodine-refractory), unresectable hepatocellular carcinoma, as well as endometrial carcinoma (in combination with pembrolizumab).
Dosage form: capsules, hard
Active substance Dosage lenvatinib 4 mg ATC: L01EX08
-
The drug is prescribed for the treatment of malignant pleural mesothelioma (in combination with cisplatin), as well as for the treatment of non-small cell lung cancer (both in combination with cisplatin and as monotherapy for maintenance or second-line treatment).
Dosage form: powder for solution for infusion
Active substance Dosage pemetrexed 100 mg ATC: L01BA04
-
The drug is prescribed for the treatment of malignant pleural mesothelioma (in combination with cisplatin), as well as for the treatment of non-small cell lung cancer (both in combination with cisplatin and as monotherapy for maintenance or second-line treatment).
Dosage form: powder for solution for infusion
Active substance Dosage pemetrexed 500 mg ATC: L01BA04
-
The drug is prescribed as first-line therapy for patients aged 65 and older with multiple myeloma who have not previously received treatment, as well as for patients who cannot undergo high-dose chemotherapy.
Dosage form: capsules, hard gelatin
Active substance Dosage thalidomide 50 mg ATC: L04AX02